( NASDAQ-NMS:WCRX,NYSE:ACT )

News from Actavis plc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Apr 13, 2015, 09:22 ET Actavis and Medicines360 Announce U.S. Availability of LILETTA™ (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Three Years

 Actavis plc (NYSE: ACT), a leading global pharmaceutical company and leader in women's health care, and Medicines360, a nonprofit women's...


Mar 17, 2015, 09:10 ET Actavis Announces Michael R. Gallagher and Peter J. McDonnell to Join Board of Directors

 Actavis plc (NYSE: ACT) today announced that two former members of the Allergan Board of Directors - Michael R. Gallagher, Lead Independent...


Mar 17, 2015, 08:55 ET Actavis Completes Allergan Acquisition

 Actavis plc (NYSE: ACT) today announced that it has completed the acquisition of Allergan, Inc. (NYSE: AGN) in a cash and equity transaction...


Mar 16, 2015, 16:05 ET Actavis Receives FDA Approval for VIIBRYD® (vilazodone HCl) 20mg Once Daily as a Therapeutic Dose

 Actavis plc (NYSE: ACT) today announced the U.S. Food and Drug Administration (FDA) has approved a lower therapeutic dose of VIIBRYD®...


Mar 16, 2015, 10:21 ET European Commission Clears Actavis' Pending Acquisition of Allergan

Actavis plc (NYSE: ACT) ("Actavis") and Allergan, Inc. (NYSE: AGN) ("Allergan") today announced that the companies received clearance from the...


Mar 13, 2015, 08:00 ET Actavis Receives FDA Approval of SAPHRIS® for Pediatric Patients (age 10-17) for Acute Treatment of Manic or Mixed Episodes of Bipolar I Disorder

 Actavis plc (NYSE: ACT) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental new drug application...


Feb 18, 2015, 07:00 ET Actavis Announces Intention to Adopt "Allergan" Corporate Name

 Actavis plc (NYSE: ACT) today announced that it will adopt a new corporate name – Allergan – following the anticipated successful...


Feb 18, 2015, 06:45 ET Actavis Outlines Standalone Pharmaceutical Pipeline at Investor Meeting

 Actavis plc (NYSE: ACT), during its Investor Meeting in New York, today provided a detailed look into its standalone global pharmaceutical...


Feb 18, 2015, 06:30 ET Actavis Non-GAAP Net Revenue Increases 44% to $4 Billion in Fourth Quarter 2014; Non-GAAP EPS Increases 23% to $3.91; Increases 2015 Standalone Forecast

 Actavis plc (NYSE: ACT) today reported exceptional performance with non-GAAP net revenue increasing 44 percent to $4.01 billion for the...


Feb 17, 2015, 17:13 ET Actavis Confirms Temporary Injunction From Appeals Court Related to Generic Pulmicort RESPULES®

 Actavis plc (NYSE: ACT) today confirmed that the United States Court of Appeals for the Federal Circuit has issued a temporary injunction to...


Feb 13, 2015, 16:28 ET Actavis Launches Generic Pulmicort RESPULES®

 Actavis plc (NYSE: ACT) today announced that it has launched its generic version of AstraZeneca's Pulmicort RESPULES® (budesonide...


Feb 13, 2015, 08:30 ET Actavis to Divest Pharmatech to TPG

 Actavis plc (NYSE: ACT) and TPG, the global private investment firm, today announced that they have entered into definitive agreements, under...


Feb 13, 2015, 08:00 ET Actavis launches the "Unconditional Love" Campaign to Recognize Alzheimer's Disease Caregivers

Actavis plc, a leading global specialty pharmaceutical company, today announced the launch of the "Unconditional Love" campaign, which recognizes...


Feb 09, 2015, 17:23 ET Actavis to Divest Doryx® to Mayne Pharma

 Actavis plc (NYSE: ACT) today announced that it has entered into an agreement with Mayne Pharma, under which it will divest the U.S. rights to...


Feb 05, 2015, 02:05 ET Actavis to Divest Rights to Branded Respiratory Portfolio in the U.S. and Canada to AstraZeneca

Actavis plc (NYSE: ACT) and AstraZeneca today announced that they have entered into a definitive agreement under which AstraZeneca will acquire the...


Feb 04, 2015, 08:00 ET Actavis Announces FDA Acceptance of sNDA to Expand TEFLARO® (ceftaroline fosamil) Labeling

Actavis plc (NYSE: ACT) today announced that the U.S. Food and Drug Administration (FDA) has accepted for...


Jan 26, 2015, 17:30 ET Actavis Registration Statement for Pending Acquisition of Allergan Declared Effective by the SEC

 Actavis plc (NYSE: ACT) and Allergan, Inc. (NYSE: AGN) today announced that the U.S. Securities and Exchange Commission has declared effective...


Jan 26, 2015, 07:30 ET Actavis to Acquire Auden Mckenzie for 306M GBP

 Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, and the owners of Auden Mckenzie Holdings Limited, a dynamic and...


Jan 20, 2015, 02:00 ET Richter and Actavis Announce Positive Phase III Results for Cariprazine in the Prevention of Relapse in Patients with Schizophrenia

 Gedeon Richter Plc. and Actavis plc (NYSE: ACT) today announced positive results from a Phase III trial evaluating the efficacy and safety of...


Jan 13, 2015, 08:00 ET Actavis Launches U.S. Generic Specialty Injectable Portfolio

 Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced the launch of a leading portfolio of generic...


Jan 12, 2015, 08:30 ET Actavis Announces Exceptional Preliminary Fourth Quarter 2014 Performance

 Actavis plc (NYSE: ACT), in advance of the start of  the 33rd Annual J.P. Morgan Healthcare Conference, today announced that based on a...


Jan 12, 2015, 08:00 ET Actavis and Allergan Announce Early Termination of Hart-Scott-Rodino Waiting Period for Actavis' Pending Acquisition of Allergan and Record Dates for Shareholder Meetings

 Actavis plc (NYSE: ACT) and Allergan, Inc. (NYSE: AGN) today announced that the U.S. Federal Trade Commission (FTC) has granted early...


Jan 06, 2015, 15:54 ET Actavis Confirms Appeals Court Grants Expedited Appeal of Ruling Requiring Continued Distribution of NAMENDA® IR

 Actavis plc (NYSE: ACT) today confirmed that the U.S. Court of Appeals for the Second Circuit granted the Company's motion to expedite its...


Jan 06, 2015, 02:00 ET Actavis and Gedeon Richter Announce FDA Receipt of NDA Resubmission for Cariprazine

Actavis plc (NYSE: ACT) and Gedeon Richter Plc. today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of...


Dec 24, 2014, 13:15 ET Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension

 Actavis plc (NYSE: ACT) today confirmed that the Company has received a complete response letter from the U.S. Food and Drug Administration...